Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION

Comorbidities in patients with CML may influence treatment-related decisions and impact response and survival. Retrospective analysis of 1-year data from the phase 3 DASISION study reported that baseline comorbidity did not substantially impact outcomes in dasatinib- or imatinib-treated patients.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Michael J. Mauro, Jorge E. Cortes, Andreas Hochhaus, Neil P. Shah, Ehab L. Atallah, Mena Abaskharoun, Oumar Sy, Giuseppe Saglio Source Type: research